PubRank

Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer

Clinical Trial ID NCT01195415

PubWeight™ 24.82‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01195415

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The pancreas cancer microenvironment. Clin Cancer Res 2012 4.10
2 G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov 2011 3.31
3 Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nat Med 2013 2.55
4 Overcoming drug resistance in pancreatic cancer. Expert Opin Ther Targets 2011 1.36
5 Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progression. J Surg Res 2011 1.31
6 Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma. Clin Cancer Res 2014 1.20
7 Desmoplasia in pancreatic cancer. Can we fight it? Gastroenterol Res Pract 2012 0.96
8 Current and future systemic treatment options in metastatic pancreatic cancer. J Gastrointest Oncol 2014 0.95
9 Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors. Cancers (Basel) 2016 0.91
10 Carcinogenesis of pancreatic adenocarcinoma: precursor lesions. Int J Mol Sci 2013 0.91
11 Wound healing and cancer stem cells: inflammation as a driver of treatment resistance in breast cancer. Cancer Growth Metastasis 2015 0.90
12 Cooperative integration between HEDGEHOG-GLI signalling and other oncogenic pathways: implications for cancer therapy. Expert Rev Mol Med 2015 0.87
13 Can nanomedicines kill cancer stem cells? Adv Drug Deliv Rev 2013 0.86
14 Sonic Hedgehog in pancreatic cancer: from bench to bedside, then back to the bench. Surgery 2012 0.83
15 Contribution of epithelial-mesenchymal transition to pancreatic cancer progression. Cancers (Basel) 2010 0.82
16 Anti-Cancer Stem-like Cell Compounds in Clinical Development - An Overview and Critical Appraisal. Front Oncol 2016 0.80
17 Targeted therapies for pancreatic adenocarcinoma: Where do we stand, how far can we go? World J Gastrointest Oncol 2015 0.78
18 Targeting stromal microenvironment in pancreatic ductal adenocarcinoma: controversies and promises. J Gastrointest Oncol 2016 0.76
19 Investigational agents in metastatic basal cell carcinoma: focus on vismodegib. J Exp Pharmacol 2012 0.75
20 Differential role of Hedgehog signaling in human pancreatic (patho-) physiology: An up to date review. World J Gastrointest Pathophysiol 2016 0.75
Next 100